Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

Your Environment. Your Health.

Progress Reports: Oregon State University: PAHs in Humans at Environmental Levels: Pharmacokinetics, Metabolism and Susceptible Individuals

Superfund Research Program

PAHs in Humans at Environmental Levels: Pharmacokinetics, Metabolism and Susceptible Individuals

Project Leader: David E. Williams
Grant Number: P42ES016465
Funding Period: 2013-2020
View this project in the NIH Research Portfolio Online Reporting Tools (RePORT)

Learn More About the Grantee

Visit the grantee's eNewsletter page Visit the grantee's eNewsletter page Visit the grantee's Twitter page Visit the grantee's Facebook page Visit the grantee's Video page

Progress Reports

Year:   2019  2018  2017  2016  2015  2014  2013 

Specific Aim 1: Conduct the first pharmacokinetic study of benzo[a]pyrene (BaP) in humans.

The pharmacokinetics of [14C]-BaP(eq) with multiple dosings over varying time intervals showed low intra-individual variability that was independent of time between exposures. This finding is of significance as it strongly suggests the absorption, metabolism, and excretion of BaP (and perhaps other polyaromatic hydrocarbons, or PAHs) is consistent over time for a given individual and not strongly influenced by extrinsic factors.

Specific Aim 2: Conduct the first evaluation of the Relative Potency Factor (RPF) approach to risk assessment for PAHs in human studies.

Consumption of canned salmon, at an amount equivalent to smoked salmon containing a complex mixture of PAHs at 10-X BaP(eq) as determined by the RPF, showed their previous conclusion regarding the impact of co-exposure on the pharmacokinetics of [14C]-BaP(eq) was not due to the PAHs, but rather to the food matrix. Therefore, the hypothesis that the RPF approach could be used for risk assessment following human dietary exposures to PAH mixtures could not be rejected. This is of significance as in vitro studies with human cell lines and in vivo animal tumor models have called into question the validity of the RPF approach to risk assessment for PAH mixtures.

Specific Aim 3: Conduct the first assessment of gene-environment interactions in humans at environmentally relevant levels of exposure to PAHs.

Covalent DNA adduction has been the most frequently used biomarker for cancer risk assessment of environmental carcinogens including BaP. A time course study has shown that, at a realistic environmental exposure to [14C]-BaP, there is no detectable binding to DNA of peripheral blood mononuclear cells. The question of linearity of this biomarker and its value as a risk assessment tool is still being examined. With the high sensitivity of accelerator mass spectrometry, the researchers can say that following a defined dose of 46 nanograms, the level of peripheral blood mononuclear cell DNA adducts is <1 in 10^11 nucleotides, two to three orders of magnitude lower than reported in lymphocytes of occupationally-exposed populations. As they found no covalent adduction in any subject, relating risk to genotype was not possible.

to Top